STOCK TITAN

Bluejay Diagnostics, Inc. - BJDX STOCK NEWS

Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.

Bluejay Diagnostics, Inc. (symbol: BJDX) is a pioneering medical diagnostics company dedicated to enhancing patient outcomes through its innovative Symphony System.

The Symphony System is a cost-effective, rapid, and near-patient diagnostic solution designed for the triage and monitoring of disease progression. Bluejay Diagnostics is at the forefront of medical technology, utilizing whole blood samples to deliver quick and accurate results. This is particularly crucial in critical care settings where timely information can significantly impact patient care.

The company's flagship product, the Symphony IL-6 test, is instrumental for healthcare providers. It measures an established inflammatory biomarker, Interleukin-6 (IL-6), which is vital for assessing the severity of infections and inflammations, including sepsis. The IL-6 test aids in early diagnosis and effective management of various critical conditions, ultimately improving patient outcomes.

Recent achievements highlight Bluejay Diagnostics' commitment to advancing medical diagnostics. As of the latest financial updates, the company has reported significant progress in its financial results for the six and three months ended June 30 and September 30, 2023, respectively. These results reflect the company's steady growth and strategic efforts in enhancing its product offerings and expanding its market reach.

Bluejay Diagnostics is guided by a vision of leveraging cutting-edge technology to meet the urgent needs of healthcare providers and patients. The company continues to explore new advancements and potential partnerships to further its mission of improving diagnostic accuracy and patient care efficiency.

For investors and stakeholders, the company offers regular updates and maintains open communication through its dedicated investor contacts:

  • Alexandra Schuman, LifeSci Advisors, alex@lifesciadvisors.com, t: 646-876-3647
  • Neil Dey, Bluejay Diagnostics, Inc., Tel: 978-631-0310, Email: neil.dey@bluejaydx.com
  • Bluejay Diagnostics, ir@bluejaydx.com, t: 978-631-0310
Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) has announced the closing of its $8.75 million underwritten public offering, completed on June 28, 2024.

This offering included 5,368,098 Common Units or Prefunded Units, each priced at $1.63 and $1.6299 respectively. The proceeds will be used to repay $2.3 million in outstanding debt and to fund FDA approval processes and general working capital needs.

This offering includes several warrant types, such as Class C and Class D Warrants, which have specific exercise prices and expiration terms. Aegis Capital Corp. acted as the underwriter, and the offering was made under SEC registration statement Form S-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.77%
Tags
-
Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) announced the pricing of an $8.75 million underwritten public offering. The offering includes 5,368,098 Common Units or Prefunded Units, each with one share of common stock or one pre-funded warrant and three types of warrants for additional stock purchases. The company set the purchase price for Common Units at $1.63 and Prefunded Units at $1.6299. Proceeds will be used to repay $2.3 million of outstanding debt, fund FDA approval-related activities, and support R&D and working capital. The offering is expected to close on June 28, 2024, with Aegis Capital Corp. as the underwriter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.99%
Tags
-
Rhea-AI Summary

Bluejay Diagnostics announced the primary results of their SYMON-I pilot clinical study, which suggests that interleukin-6 (IL-6) can predict mortality in sepsis and septic shock patients within 28 days of ICU admission. The study compared IL-6 levels to standard clinical tests like lactate and SOFA, finding IL-6 to be a more reliable predictor of mortality. The results will be validated in the SYMON-II study set to begin in Q3 2024. Positive results from SYMON-II could support a 510(k) application to the FDA in 2025. The company aims to present these results at scientific meetings and publish them in peer-reviewed journals, contingent on raising additional capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.73%
Tags
none
Rhea-AI Summary

Bluejay Diagnostics announced a 1-for-8 reverse stock split effective June 20, 2024. This will reduce outstanding shares from approximately 4.5 million to around 564,000, with no change in par value. Fractional shares will be compensated in cash. The stock will trade under the same symbol, BJDX, but with a new CUSIP number. The reverse split affects all shareholders uniformly, preserving their percentage ownership except for fractional share adjustments. The transfer agent for this process is Continental Stock Transfer & Trust Company. Bluejay focuses on rapid diagnostics to improve patient outcomes in critical care settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.43%
Tags
-
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the closing of a public offering of 2,692,308 shares of common stock and warrants, generating approximately $3.5 million in gross proceeds. The company intends to use the net proceeds for obtaining FDA approval, clinical studies, research and development, and general working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
-
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the pricing of a public offering of 2,692,308 shares of common stock and warrants to purchase up to 2,692,308 shares at a combined offering price of $1.30 per share. The offering is expected to close on December 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.48%
Tags
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announces the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients, positioning the company to move forward with multiple initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.5%
Tags
-
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported its financial results for the quarter and nine months ended September 30, 2023. The company focused on implementing a modified clinical strategy based on FDA feedback and plans to submit for regulatory approval for Symphony IL-6 in the first half of 2024. Bluejay renegotiated its licensing and supply agreements with Toray Industries, Inc., reducing royalty payments and securing critical component supply for the Symphony Cartridge. Symphony IL-6 testing has the potential to improve outcomes for sepsis patients by enabling healthcare providers to better prioritize care. Cash and cash equivalents on September 30, 2023, were $5.08 million, with an estimated sufficient fund to operate into the first quarter of 2024. The company expects to seek additional capital through various means for its planned operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
-
Rhea-AI Summary
Bluejay Diagnostics, Inc. announces purchase and sale of 216,000 shares of common stock in a registered direct offering and concurrent private placement. Gross proceeds expected to be approximately $1.59 million. Net proceeds to be used for FDA approval, research and development, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.63%
Tags
Rhea-AI Summary
Bluejay Diagnostics, Inc. announced financial results for the six months ended June 30, 2023. The company is developing the Symphony IL-6 test on its Symphony platform, which has the potential to predict clinical deterioration in sepsis patients. The company submitted a pre-submission application to the FDA and intends to proceed as planned based on the FDA's feedback. Cash and cash equivalents on June 30, 2023, were $5.1 million. Research and development expenses increased to $3.0 million, while general and administrative expenses decreased slightly to $2.3 million. Sales and marketing expenses increased to $302,000. The net loss for the six months ended June 30, 2023, was $5.4 million, or $5.24 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags

FAQ

What is Bluejay Diagnostics, Inc. known for?

Bluejay Diagnostics, Inc. is known for its Symphony System, a rapid and cost-effective near-patient diagnostic solution for triage and disease monitoring.

What is the Symphony IL-6 test?

The Symphony IL-6 test measures Interleukin-6, an inflammatory biomarker used to assess the severity of infections and inflammations such as sepsis.

How does Bluejay Diagnostics' technology benefit critical care settings?

The Symphony System provides rapid and accurate diagnostic results using whole blood samples, aiding in timely decision-making and improved patient outcomes in critical care.

What recent financial results has Bluejay Diagnostics reported?

Bluejay Diagnostics recently reported its financial results for the six and three months ended June 30 and September 30, 2023, indicating steady growth and strategic advancements.

Who should be contacted for investor relations at Bluejay Diagnostics?

For investor relations, you can contact Alexandra Schuman at LifeSci Advisors, Neil Dey at Bluejay Diagnostics, or email ir@bluejaydx.com.

What does the Symphony System use for testing?

The Symphony System uses whole blood samples to perform rapid diagnostic tests.

What is the main focus of Bluejay Diagnostics?

The main focus of Bluejay Diagnostics is to improve patient outcomes through innovative diagnostic technologies that provide timely and accurate information.

How does the Symphony IL-6 test help in managing sepsis?

The Symphony IL-6 test helps by measuring an inflammatory biomarker that indicates the severity of sepsis, aiding in early diagnosis and effective management.

What are the benefits of using Bluejay Diagnostics' products?

Benefits include rapid and accurate diagnostics, cost-effective testing, and improved patient outcomes, especially in critical care settings.

Where can I find more information about Bluejay Diagnostics?

More information can be found on Bluejay Diagnostics' website or by contacting their investor relations representatives.

Bluejay Diagnostics, Inc.

Nasdaq:BJDX

BJDX Rankings

BJDX Stock Data

3.60M
560.00k
10%
9.5%
2.66%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ACTON